Pietrantonio F, et al. - Researchers developed a nomogram, on a set of 320 Italian patients, for predicting the overall survival (OS) probability of advanced gastric cancer patients receiving second-line treatment. They also sought for external validation of this nomogram on two independent sets (295 Italian and 172 Korean patients). Calibration plot and C index were used to assess the nomogram’s performance. They noted that, the C index was 0.72 and 0.69 in the development set and in the Italian validation set, respectively, but only 0.57 in the Korean set. Overall, this nomogram could have utility in the prediction of 3- or 6-month OS in Caucasian gastric cancer patients eligible for second-line therapy. The Gastric Life nomogram, based on three easy-to-collect variables, could offer improved patient selection for second-line treatments and assist in clinical trial enrollment.